The incidence of (para) thyroid disorders ten years after the introduction of a new thyroid protection during 131I-MIBG treatment in children with neuroblastoma

The incidence of (para) thyroid disorders ten years after the introduction of a new thyroid protection during 131I-MIBG treatment in children with neuroblastoma - (Para)-Thyroid damage after 131I-MIBG treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37078

Enrollment

Registered

2013-02-19

Start date

2013-03-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothyroidism thyroid dysfunction thyroid nodules

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: All neuroblastoma patients treated with 131I-MIBG, in the period 1999 until 2011 (who received the DBR profylaxe for thyroid protection) in Emma Children*s Hospital and Sophia Children*s Hospital will be evaluated and included in the study

Exclusion criteria

Exclusion criteria: All neuroblastoma patients who were not treated with 131I-MIBG .

Design outcomes

Primary

Measure	Time frame
Thyroid dysfunction (TSH and FT4) and the occurrence of thyroid nodules/carcinoma. Thyroid dysfunction is defined as having TSH > 4.5 mU/L or using T4 at the last moment of follow-up.	—

Secondary

Measure	Time frame
Incidence of hyperparathyroidism and the occurrence of adenomas in the parathyroid glands.	—

Countries

Netherlands

Outcome results